Agenus (AGEN) vs Precision BioSciences (DTIL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Precision BioSciences (DTIL) has outperformed Agenus (AGEN) over the past year, gaining 48.0% versus a gain of 41.5%. Over five years, AGEN leads with a -90.6% price change compared with -97.2% for DTIL. Precision BioSciences is the larger company by market cap ($282.5 million vs $270.1 million), about 1.0 times the size, while Agenus is growing revenue faster (+10.4% vs -50.1%).
On valuation, Agenus trades at a lower trailing P/E (26.0x vs 29.6x for Precision BioSciences). Agenus converts more of its revenue into profit, with a net margin of -2.7% versus -133.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AGEN | DTIL |
|---|---|---|
| Share price | $5.97 | $7.40 |
| Market cap | $270.12M | $282.46M |
| 1-day change | -2.77% | +7.09% |
| YTD return | +90.13% | +77.88% |
| 1-year return | +41.47% | +48.00% |
| 5-year return | -90.58% | -97.23% |
| P/E ratio (TTM) | 25.96 | 29.60 |
| EPS (TTM) | $0.23 | $0.25 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $114.20M | $34.26M |
| Revenue growth (YoY) | +10.37% | -50.12% |
| Net income (latest FY) | $-3.08M | $-45.72M |
| Gross margin | 99.11% | — |
| Operating margin | -17.66% | -152.19% |
| Net margin | -2.70% | -133.45% |
| 52-week high | $10.31 | $11.29 |
| 52-week low | $2.71 | $3.53 |
| Distance from 52-week high | -42.10% | -34.46% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +352.26% | +297.30% |
| Average volume | 905.17K | 319.79K |
| Shares outstanding | 45.25M | 38.17M |
| Employees | 81 | 69 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Agenus is more profitable, keeping -2.7 cents of every revenue dollar as net income versus -133.4 cents for Precision BioSciences.
- Agenus grew revenue faster in its latest fiscal year (+10.37% vs -50.12%).
About Agenus
AGEN stock →Agenus Inc., a clinical-stage biotechnology company, discovers and develops immunotherapies for cancer and infectious diseases in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 81 employees
About Precision BioSciences
DTIL stock →Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARCUS, a genome editing platform for DNA genome insertion, removal, and repair.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 69 employees
AGEN vs DTIL FAQ
Which is bigger, Agenus or Precision BioSciences?
Precision BioSciences (DTIL) is larger, with a market capitalization of $282.46M compared with $270.12M for Agenus (AGEN).
Which stock has performed better over the past year, AGEN or DTIL?
DTIL returned +48.00% over the past 12 months, compared with +41.47% for AGEN (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, AGEN or DTIL?
AGEN has the lower trailing P/E at 26.0, versus 29.6 for DTIL. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Agenus and Precision BioSciences in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.